Objective   To investigate the effect of sulodexide combined with angiotensin receptor blocker (ARB)

valsartan on IgA nephropathy（IgAN）.  Methods   Fiftyfour cases with pathologicallydiagnosed IgAN

whose renal pathologic change were between grade Ⅱ to Ⅳ according to Lee’s grading and the quantity of urine protein were less than 3.5 g

admitted in our department from June 2009 to January 2010 were randomized equally into 2 groups

Sulodexide +ARB group (treated intravenously with a 600 LSU Sulodexide qd for 4 weeks

and then orally with 250 LSU bid for 8 weeks. At the same time

valsartan 80 mg/d

po for 12 weeks) and ARB group (valsartan 80 mg/d

po for 12 weeks). Therapeutic effect of these 2 treatment in a 3-month follow-up was evaluated by the quantity of urine protein

levels of creatinine

plasma fibrinogen

prothrombin time

activated partial thromboplastin time

triglyceride

and total cholesterol.  Results  After 3 months of treatment

the quantity of urine protein was reduced by 48.46% and 24.75% respectively in Sulodexide+ARB group and ARB group. Significant difference was noted in the quantity of urine protein between the 2 groups (P0.05). The effective rate was 88.24% and 45.45% in Sulodexide+ARB group and ARB group for the patients with glomerular scores more than 7

and significant difference was observed between the 2 groups (P0.05). Compared with ARB group

plasma fibrinogen

triglycerin

and total cholesterol were obviously decreased in Sulodexide+ARB group after 3 months’ treatment (P0.05). There was no significant difference in serum creatinine in Sulodexide+ARB group after treatment

but in ARB group

the value was sigificantly increased than before treatment (P0.05).  Conclusion  Sulodexide combined ARB is safe and effective in treating IgAN patients

especially for those with whose glomerular scores over 7

and the  Results  are significantly better than those treated with ARB alone.